Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHP465 mixed amphetamine salts
- Development stage
- Phase 3
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SHP465 mixed amphetamine salts is a once-daily, extended-release oral formulation designed for the treatment of attention-deficit/hyperactivity disorder (ADHD). It utilizes a unique triple-bead technology to provide immediate-release and two types of delayed-release profiles, resulting in up to 16 hours of therapeutic coverage. Each capsule contains equal amounts by weight of four different amphetamine salts—dextroamphetamine sulfate, amphetamine sulfate, dextroamphetamine saccharate, and amphetamine aspartate monohydrate—in a 3:1 ratio of dextroamphetamine to levoamphetamine base equivalents. The mechanism of action involves blocking the reuptake and increasing synaptic concentrations of norepinephrine and dopamine in the brain[2][3][4][5].
- Brand names
- Mydayis
- Other names
- SHP465 MASSHP-465 MASSHP 465 MAStriple-bead mixed amphetamine saltsmixed salts of a single-entity amphetamine extended release capsule
02
Targets
DAT (Dopamine plasma membrane transport protein)TAAR1 (Trace amine-associated receptor 1)NET (Norepinephrine Transporter)VMAT2 (Vesicular monoamine transporter 2)COMT (Catechol-O-methyltransferase)MAOA (Monoamine oxidase A)
Beyond the preview
Go deeper on SHP465 mixed amphetamine salts.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHP465 mixed amphetamine salts.